Xerostomia Therapeutics Global Market Report 2026

Xerostomia therapeutics are treatments and medications designed to address dry mouth, a condition marked by decreased saliva production. These therapies work to relieve symptoms like difficulty in swallowing and tasting, while also helping to prevent dental problems.

The primary forms of xerostomia treatments include artificial saliva or saliva substitutes, as well as salivary stimulants. Artificial saliva or saliva substitutes are formulations created to replicate the natural characteristics of saliva, offering lubrication, hydration, and protection to the oral tissues. They are made available through multiple distribution channels such as hospital pharmacies, retail pharmacies, drugstores, mail-order pharmacies, and hypermarkets and supermarkets, catering to both adult and pediatric users.

Tariffs have impacted the xerostomia therapeutics market by increasing the cost of imported excipients, packaging materials, and specialized oral care formulation inputs. These effects are most evident in artificial saliva substitutes and prescription stimulant therapies, particularly in regions that depend heavily on imported materials. Rising tariff related costs have placed upward pressure on retail pricing and reimbursement dynamics. This may limit patient accessibility in cost sensitive markets and public healthcare systems. However, tariffs are also encouraging local manufacturing of oral care therapeutics, private label production, and stronger regional supply capabilities over time.

The xerostomia therapeutics market research report is one of a series of new reports from The Business Research Company that provides xerostomia therapeutics market statistics, including xerostomia therapeutics industry global market size, regional shares, competitors with a xerostomia therapeutics market share, detailed xerostomia therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the xerostomia therapeutics industry. This xerostomia therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The xerostomia therapeutics market size has grown steadily in recent years. It will grow from $2.24 billion in 2025 to $2.35 billion in 2026 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historic period can be attributed to aging population, widespread use of xerogenic drugs, rising prevalence of chronic diseases, increased dental awareness, hospital-based symptom management.

The xerostomia therapeutics market size is expected to see steady growth in the next few years. It will grow to $2.79 billion in 2030 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to growth in otc product availability, increasing cancer therapy side effects, rising self-medication trends, expansion of pharmacy networks, higher focus on quality of life treatments. Major trends in the forecast period include rising incidence of medication-induced dry mouth, growing demand for over-the-counter therapies, increased adoption of artificial saliva products, expansion of retail and mail-order pharmacies, higher focus on oral symptom management.

The increasing prevalence of chronic diseases is anticipated to drive the growth of the xerostomia therapeutics market in the coming years. Chronic diseases are long-term medical conditions that persist for months or years, often developing gradually and requiring continuous management. The rising prevalence of chronic diseases is largely attributed to sedentary lifestyles, as insufficient physical activity contributes to obesity, cardiovascular disorders, diabetes, and other prolonged health issues. Xerostomia therapeutics aid in managing chronic diseases by relieving dry mouth symptoms and enhancing oral health, nutrition, and medication compliance, all of which are essential for effective long-term disease management. For example, in June 2024, according to the National Health Service, a UK-based government agency, 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023, representing an 18% rise from 3,065,825 cases in 2022. Consequently, the growing prevalence of chronic diseases is fueling the expansion of the xerostomia therapeutics market.

The increasing geriatric population is anticipated to drive the growth of the xerostomia therapeutics market in the coming years. The geriatric population refers to the rising number of individuals aged 65 years and above within the global demographic landscape. This growth is fueled by declining fertility rates and increasing life expectancy worldwide. The xerostomia therapeutics market caters to older adults by offering saliva-stimulating agents and oral moisturizers that alleviate dry-mouth symptoms, supporting chewing, swallowing, and proper nutrition. For example, in July 2024, according to the UK Parliament's House of Commons Library, a UK-based government body, there were 12.7 million people aged 65 or older in the UK in 2022, accounting for 19% of the total population. This figure is projected to increase to 22.1 million by 2072, representing 27% of the population. Hence, the rising geriatric population is contributing to the expansion of the xerostomia therapeutics market.

Major companies in the xerostomia therapeutics market are emphasizing patient-friendly, non-invasive solutions, such as oral sprays that deliver targeted lubrication and protective coverage throughout the mouth to alleviate dry-mouth symptoms and promote oral health. Oral sprays for xerostomia are formulations administered as a fine mist directly onto the oral mucosa (tongue, palate, inner cheeks), forming either a hydrating layer or lipid-based coating to minimize moisture loss, improve lubrication during chewing, swallowing, and speaking, and provide longer-lasting relief for individuals experiencing dry mouth. For example, in July 2023, K Pharmaceuticals, a US-based (with Indian origins) pharmaceutical company, introduced Aquoral, a clinically validated oral spray for xerostomia management that utilizes patented Oxidized Glycerol Triesters (OGT) lipid technology to create a durable protective barrier in the oral cavity, offering up to six hours of relief, requiring only two quick sprays, and reducing the need for frequent reapplication compared to aqueous-based options.

Major companies operating in the xerostomia therapeutics market are GlaxoSmithKline plc, Colgate-Palmolive Company, Sun Pharmaceutical Industries Ltd., Cipla Ltd., Synedgen Inc., Mission Pharmacal Company, Dentaid Ltd., Sunstar Suisse S.A., Forward Science Holding Inc., OraCoat, Oralieve UK Ltd., OraPharma Inc., OraVital Inc., Saliwell Limited, Bayer AG, 3M Company, Church & Dwight Co. Inc., Hikma Pharmaceuticals PLC, Lupin Limited, Teva Pharmaceutical Industries Ltd.

North America was the largest region in the xerostomia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the xerostomia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the xerostomia therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The xerostomia therapeutics market consists of revenues earned by entities by providing services such as medical consultations, pharmacological assistance, dental care, patient education, support services, and research and development, all geared towards treating and managing dry mouth. The market value includes the value of related goods sold by the service provider or included within the service offering. The xerostomia therapeutics market also includes sales of oral moisturizers, dental products such as fluoride treatments and saliva-stimulating mouthwashes, and oral lubricants. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Xerostomia Therapeutics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses xerostomia therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for xerostomia therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The xerostomia therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Artificial Saliva Or Saliva Substitutes; Salivary Stimulants
• 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Drug Stores; Mail Order Pharmacies; Hypermarkets And Supermarkets
• 3) By End-User: Adult; Pediatric
• Subsegments:
• 1) By Artificial Saliva Or Saliva Substitutes: Oral Sprays; Gels; Lozenges; Mouthwashes
• 2) By Salivary Stimulants: Prescription Drugs; Over-The-Counter (Otc) Products; Chewing Gums And Lozenges
• Companies Mentioned: GlaxoSmithKline plc; Colgate-Palmolive Company; Sun Pharmaceutical Industries Ltd.; Cipla Ltd.; Synedgen Inc.; Mission Pharmacal Company; Dentaid Ltd.; Sunstar Suisse S.A.; Forward Science Holding Inc.; OraCoat; Oralieve UK Ltd.; OraPharma Inc.; OraVital Inc.; Saliwell Limited; Bayer AG; 3M Company; Church & Dwight Co. Inc.; Hikma Pharmaceuticals PLC; Lupin Limited; Teva Pharmaceutical Industries Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.